CellaVision ABCVLLY +12.06%69 PE Ratio without NRI is 23.61 as of Jun. 24, 2026, which is 54% below its 10-year median of 51.13. GuruFocus rates CVLLY with a GF Score™ of 69/100 and a GF Value™ of $12.48 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 448 Medical Devices & Instruments companies, CellaVision AB ranks worse than 53.13% on this metric.
The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. As of today (2026-06-24), CellaVision AB's share price is $7.06.
CellaVision AB's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was $0.30. Therefore, CellaVision AB's PE Ratio without NRI for today is 23.61.
During the past 13 years, CellaVision AB's highest PE Ratio without NRI was 109.22. The lowest was 21.07. And the median was 51.13.
During the past years, CellaVision AB's highestPE Ratio (TTM) was 109.22. The lowest was 21.07. And the median was 51.13.
CellaVision AB's
EPS (Diluted) for the
three
months ended in Mar. 2026 was $0.05.
Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $0.30.
CellaVision AB's EPS (Basic) for the
three
months ended in Mar. 2026 was $0.05.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was $0.30.
CellaVision AB (OTCPK:CVLLY) PE Ratio without NRI Explanation
The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.
In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.
If a company loses money, the PE Ratio becomes meaningless.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.
Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.
Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.
CellaVision AB PE Ratio without NRI Related Terms
CellaVision AB PE Ratio without NRI Historical Data
* Premium members only.
The historical data trend for CellaVision AB's PE Ratio without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CVLLY vs ABT, SYK, MDT: PE Ratio without NRI Comparison
For the Medical Devices subindustry, CellaVision AB's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CellaVision AB PE Ratio without NRI vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, CellaVision AB's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where CellaVision AB's PE Ratio without NRI falls into.
The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. Regular PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.
CellaVision AB's PE Ratio without NRI for today is calculated as
CellaVision AB's Share Price of today is $7.06.
CellaVision AB's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.30.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.
In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.
In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months.
For Forward PE Ratio, the earnings are the expected earnings for the next twelve months.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.
CellaVision AB (CVLLY) has a PE Ratio without NRI of 23.61 as of Jun. 24, 2026. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on CellaVision AB and its competitors. This is 54% below median its historical median of 51.13. Over the past decade, CellaVision AB's PE Ratio without NRI has ranged from 21.07 to 109.22. According to the industry distribution chart, CellaVision AB ranks #238 out of 448 companies in the Medical Devices & Instruments industry, placing it in the top 53.1%.
Is CellaVision AB's PE Ratio without NRI too high?
CellaVision AB's current PE Ratio without NRI of 23.61 is 54% below median its 10-year median of 51.13. Over the past 10 years, this metric has ranged from a low of 21.07 to a high of 109.22. The Medical Devices & Instruments industry median PE Ratio without NRI is 23.28. CellaVision AB's value of 23.61 is 1.4% above this industry median. Based on the distribution chart, CellaVision AB ranks #238 out of 448 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, CellaVision AB has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CellaVision AB's PE Ratio without NRI compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, CellaVision AB ranks #238 out of 448 companies for PE Ratio without NRI. This places CellaVision AB in the lower half of its industry. The industry median PE Ratio without NRI is 23.28. CellaVision AB's value of 23.61 is 1.4% above this benchmark. Historically, CellaVision AB's own PE Ratio without NRI has ranged from 21.07 to 109.22 over the past decade. While the company's 10-year median is 51.13 vs. the industry median of 23.28, CellaVision AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio without NRI for a Medical Devices & Instruments company?
The median PE Ratio without NRI among Medical Devices & Instruments companies is 23.28, based on 448 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio without NRI significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CellaVision AB's current PE Ratio without NRI of 23.61 is 1.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio without NRI mean?
A high PE Ratio without NRI can signal that a stock is expensive relative to its fundamentals. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on CellaVision AB and its competitors. For the Medical Devices & Instruments industry, the median PE Ratio without NRI is 23.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CellaVision AB's current PE Ratio without NRI is 23.61, which is 54% below median its own 10-year median of 51.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CellaVision AB stock overvalued right now?
Based on GuruFocus' analysis, CellaVision AB (CVLLY) is currently considered Significantly Undervalued. The stock's GF Value™ is $12.48, compared to a current price of $7.06 — trading 43.4% below its estimated fair value. The current PE Ratio without NRI is 23.61, which is 54% below median its 10-year median of 51.13 and 1.4% above the Medical Devices & Instruments industry median of 23.28. CellaVision AB's overall GF Score™ is 69/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio without NRI calculated?
PE Ratio without NRI is calculated from a company's financial statements. For CellaVision AB (CVLLY), the current PE Ratio without NRI is 23.61 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CellaVision AB (CVLLY) Overvalued in 2026?
Based on GuruFocus' analysis, CellaVision AB stock appears to be undervalued.
The current stock price of $7.06 is trading 43.4% below its estimated GF Value™ of $12.48.
GuruFocus considers CellaVision AB to be Significantly Undervalued.
Key valuation signals for CVLLY:
PE Ratio without NRI: 23.61 (54% below median its 10-year median of 51.13)
GF Value™: $12.48 vs. price of $7.06 (43.4% below fair value)
Industry Position: 1.4% above the Medical Devices & Instruments median (#238 of 448)
No single metric tells the full story. See the CVLLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CellaVision AB is engaged in developing and selling instruments, software, and reagents for blood and body fluid analysis. The company automates parts of the sample preparation process and replaces manual microscopes with instruments based on digital image analysis technology and artificial intelligence. The solutions contribute to more effective workflows and higher quality in laboratory medicine. The product offer consists of products and solutions for standardized laboratory diagnostics and improved performance for cellular image processing and systems for digital microscopy in hematology, consisting of reagents, instruments, and supplementary software and peripheral equipment.
69GF Score
Get the complete analysis for CVLLY
PE Ratio without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CVLLY has been successfully added to your 
